ICU Medical (ICUI) files 8-K, furnishes Q3 2025 results release

ICU Medical, Inc. (ICUI) filed a Form 8-K to report that it furnished a press release announcing its financial results for the third quarter of 2025.

Rhea-AI Filing Summary

ICU Medical, Inc. (ICUI) filed a Form 8-K to report that it furnished a press release announcing its financial results for the third quarter of 2025. The press release is provided as Exhibit 99.1 and is incorporated by reference under Item 2.02 (Results of Operations and Financial Condition). The filing lists ICU Medical’s common stock on the Nasdaq Global Select Market under the symbol ICUI. This 8-K serves to make the company’s Q3 2025 results announcement available to the market via the furnished exhibit.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did ICU Medical (ICUI) announce in its Form 8-K?

ICU Medical furnished a press release announcing its financial results for the third quarter of 2025 under Item 2.02.

Where can I find the Q3 2025 results details for ICUI?

They are in Exhibit 99.1 to the Form 8-K, which contains the press release dated November 6, 2025.

What is the Nasdaq ticker for ICU Medical?

ICU Medical’s common stock trades under the symbol ICUI on the Nasdaq Global Select Market.

Which item of the 8-K covers the results disclosure?

The results are furnished under Item 2.02: Results of Operations and Financial Condition.

Who signed the 8-K for ICU Medical?

The filing was signed by Brian M. Bonnell, Chief Financial Officer and Treasurer.

What exhibits are included with this 8-K?

Exhibit 99.1 (press release announcing Q3 2025 earnings) and Exhibit 104 (Cover Page Interactive Data File).

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/06/2025 - 04:10 PM Learn about SEC filing dates

falseICU MEDICAL INC/DE000088398400008839842025-11-062025-11-06

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) November 6, 2025

ICU MEDICAL, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-34634

33-0022692

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

951 Calle Amanecer

,

San Clemente

,

California

92673

(Address of principal executive offices)

(Zip Code)

(949) 366-2183

Registrant's telephone number, including area code

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
			☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
			☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
			☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
			☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol			Name of each exchange on which registered
Common stock, par value $0.10 per share			ICUI			The Nasdaq Stock Market LLC
						(Global Select Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition

    On November 6, 2025, ICU Medical, Inc. issued a press release announcing its financial results for the third quarter of 2025. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated in Item 2.02 by reference.

Item 9.01. Financial Statements and Exhibits.

(d)						Exhibits
99.1						Press release, dated November 6, 2025 announcing ICU Medical, Inc.'s third quarter 2025 earnings.
104									Cover Page Interactive Data File (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ICU MEDICAL, INC.

Date: November 6, 2025

By:

/s/ Brian M. Bonnell

Brian M. Bonnell

Chief Financial Officer and Treasurer